HGH Education
What is Somatropin? The Definitive Guide to Synthetic Human Growth Hormone
Somatropin is the international non-proprietary name (INN) for synthetic human growth hormone. It is a polypeptide hormone containing 191 amino acid residues with a molecular weight of approximately 22,125 daltons. Its amino acid sequence is identical to the growth hormone produced and secreted by the somatotropic cells of the anterior pituitary gland, which is why it is described as bioidentical. In practical terms, your body cannot distinguish between somatropin produced in a lab and growth hormone your pituitary releases naturally.
The terms HGH, rhGH, GH, growth hormone, and somatropin all describe the same molecule in different contexts. HGH stands for human growth hormone. rhGH stands for recombinant human growth hormone, which specifies that it was manufactured synthetically rather than extracted from biological tissue. Somatropin is the formal pharmaceutical name used by every manufacturer from Pfizer (Genotropin) and Eli Lilly (Humatrope) to independently branded products like GenXtropin HGH. You will also see the word somatotropin used interchangeably, although somatotropin technically refers to the endogenous (naturally produced) form while somatropin refers to the exogenous (manufactured) version.
The History: From Cadaver Extraction to Recombinant DNA
Before synthetic production was possible, growth hormone could only be obtained by extracting it from the pituitary glands of human cadavers. This method was used from the late 1950s until the mid 1980s. The process was slow, expensive, and yielded very small amounts of hormone per gland. Supply was severely limited, and growth hormone treatment was restricted almost exclusively to children with the most severe cases of growth hormone deficiency.
In 1985, cadaver-derived growth hormone was pulled from the market after several recipients developed Creutzfeldt-Jakob disease (CJD), a fatal prion disease transmitted through the contaminated pituitary tissue. This event accelerated the development and approval of recombinant growth hormone. The first rDNA-origin somatropin products received regulatory approval later that same year. Since then, every legitimate growth hormone product on the market has been manufactured using recombinant DNA technology, eliminating the risk of prion contamination entirely.
How Somatropin is Manufactured: The rDNA Production Process
When you see “rDNA origin” or “recombinant DNA origin” on a product label, it describes a specific and well established manufacturing process. Understanding this process helps explain why somatropin quality can vary between manufacturers and why production method matters.
The production of recombinant somatropin follows these stages:
1. Gene Insertion
The gene that encodes for human growth hormone is synthesised and inserted into a plasmid (a small circular piece of DNA). This plasmid is then introduced into a host organism. The most commonly used host is Escherichia coli (E. coli), a well understood bacterium that has been used in recombinant protein production for decades. Some manufacturers use Saccharomyces cerevisiae (yeast) as the host instead, but E. coli remains the industry standard for somatropin.
2. Fermentation
The genetically modified bacteria are grown in large scale fermentation tanks under carefully controlled conditions of temperature, pH, and nutrient supply. As the bacteria multiply, each cell reads the inserted human gene and produces the growth hormone protein. Expression is typically induced at a specific point in the growth cycle using a chemical trigger such as IPTG (isopropyl beta-D-1-thiogalactopyranoside) or a temperature shift.
3. Inclusion Body Formation
When E. coli produces somatropin at high rates, the protein tends to aggregate inside the bacterial cells and form dense, insoluble clumps called inclusion bodies. The somatropin in these inclusion bodies is biologically inactive because it is misfolded. Inclusion bodies are actually useful from a manufacturing perspective because they are easy to separate from the rest of the cell contents through centrifugation, which simplifies the initial recovery step.
4. Cell Lysis and Inclusion Body Recovery
The bacterial cells are harvested and broken open (lysed) using high pressure homogenisation or chemical methods. The cell contents are then centrifuged to separate the dense inclusion bodies from the soluble cell components, cell membranes, and debris. The inclusion body pellet is washed multiple times to remove residual bacterial proteins, DNA, and endotoxins.
5. Solubilisation and Refolding
This is the most critical step and the one that separates high quality manufacturers from low quality ones. The inclusion bodies are dissolved using denaturing agents (such as urea or guanidine hydrochloride) at an alkaline pH. This unfolds the protein completely. The somatropin is then slowly refolded into its correct three-dimensional structure by gradually removing the denaturing agents under controlled conditions. Proper refolding is what makes the protein bioactive. If this step is done poorly, the somatropin will misfold, form dimers (molecular pairs), or remain inactive.
6. Purification
The refolded somatropin is purified using a series of chromatography steps, typically ion exchange chromatography followed by size exclusion chromatography. These steps remove remaining bacterial proteins, endotoxins, misfolded variants, dimers, and other impurities. The goal is to achieve a final product that is as close to 100% pure, correctly folded, monomeric somatropin as possible.
7. Lyophilisation
The purified somatropin solution is freeze-dried (lyophilised) to remove all water while preserving the protein’s structure. The resulting white powder is stable at refrigerated temperatures for extended periods. This is why most somatropin products, including GenXtropin HGH, are supplied as lyophilised powder in sealed vials. The powder must be reconstituted with bacteriostatic water before injection.
The quality of the final product depends heavily on how well each stage is executed. Poor refolding produces high dimer content. Inadequate purification leaves bacterial endotoxins or misfolded variants in the product. Rough handling during lyophilisation or shipping can degrade the protein. This is why independent laboratory testing exists and why the results matter.
The 191 Amino Acid Sequence vs the 192 Amino Acid Problem
The growth hormone your pituitary gland produces is a chain of exactly 191 amino acids. Genuine somatropin replicates this sequence precisely. Your body’s growth hormone receptors recognise the molecule as native and respond to it without triggering an immune reaction.
In the early days of recombinant production, some manufacturers produced a 192 amino acid variant known as methionyl growth hormone (met-GH). This version retained an extra methionine residue at the N-terminus of the protein chain, a leftover from the bacterial expression process. The additional amino acid makes the molecule structurally different from native growth hormone. In some users, the immune system identifies met-GH as a foreign protein and produces antibodies against it. These antibodies can bind to the growth hormone and neutralise its activity, reducing effectiveness over prolonged use.
Modern manufacturing processes include a step that cleaves the methionine residue, producing the correct 191 amino acid sequence. However, some low cost manufacturers still sell the 192 amino acid version because the additional processing step adds cost. When evaluating a somatropin product, confirming that it uses the 191 amino acid sequence is one of the most basic quality checks you can make. Every product sold through GenXtropin UK uses the 191 amino acid sequence.
How Somatropin Works in the Body: The GH-IGF-1 Axis
Somatropin exerts its effects through two pathways: direct action on target cells and indirect action through insulin-like growth factor 1 (IGF-1). Understanding both pathways explains why growth hormone has such a wide range of effects across different tissues.
When somatropin enters the bloodstream, it binds to growth hormone receptors on cell surfaces throughout the body. At the liver, this binding triggers the production and release of IGF-1, a peptide hormone that mediates most of the growth promoting effects of GH. IGF-1 then travels through the bloodstream and acts on its own set of receptors in muscles, bones, cartilage, and organs. This two-step relay system is called the GH-IGF-1 axis, and it is the central mechanism through which growth hormone drives tissue growth and metabolic changes.
Growth hormone also acts directly on certain tissues without needing IGF-1 as an intermediary. Its direct effects on fat cells (adipocytes) are the primary driver of lipolysis, the breakdown of stored fat into free fatty acids. This is why somatropin use is associated with reductions in body fat, particularly around the midsection, independent of dietary changes.
Protein Synthesis and Muscle Growth
Somatropin promotes nitrogen retention and increases amino acid uptake into cells, pushing the body into an anabolic state. Protein synthesis is elevated while protein breakdown is suppressed. Treatment with somatropin results in an increase in both the number and size of muscle cells, a process called hyperplasia. This is distinct from the hypertrophy (cell enlargement only) caused by anabolic steroids, and it is why the two are often used together.
Fat Mobilisation
Growth hormone stimulates intracellular lipolysis directly on adipocytes. This breaks down triglycerides stored in fat cells and releases free fatty acids into the bloodstream for use as energy. In growth hormone deficient patients, somatropin administration leads to measurable reductions in total body fat, particularly visceral fat around the abdominal organs. This effect is one of the most consistently documented outcomes of GH therapy across clinical studies.
Skeletal and Connective Tissue
Via IGF-1, somatropin stimulates the growth plates (epiphyseal plates) of long bones by promoting differentiation of prechondrocytes and expansion of osteoblasts. In children, this drives linear growth. In adults whose growth plates have fused, somatropin still influences bone mineral density and connective tissue turnover, supporting stronger tendons, ligaments, and joint structures. This is particularly relevant for athletes and individuals recovering from injuries.
Organ Growth and Cell Regeneration
Somatropin influences the size of internal organs and stimulates the production of red blood cells. It promotes proportional organ growth across the body, not selective enlargement of individual organs. This regenerative capacity is also why growth hormone plays a role in wound healing, tissue repair, and recovery from physical stress.
Mineral and Electrolyte Retention
Somatropin administration results in the retention of total body potassium, phosphorus, and sodium. Serum concentrations of inorganic phosphate increase in growth hormone deficient individuals after starting treatment. Calcium levels are not significantly altered. These mineral changes reflect the increased cellular growth and metabolic activity driven by the hormone and are a measurable marker that the somatropin is biologically active.
Glucose and Insulin Interaction
Growth hormone is a modulator of carbohydrate metabolism and has a well documented diabetogenic effect at higher doses. Somatropin antagonises insulin action, which can cause insulin resistance and impaired glucose tolerance. At standard doses this effect is manageable and may even improve hypoglycaemia associated with growth hormone deficiency. At high doses or with prolonged use, monitoring fasting blood glucose and HbA1c levels becomes important to catch any shift toward insulin resistance early.
Pharmacokinetics: How Somatropin Moves Through Your Body
Understanding how somatropin is absorbed, distributed, and eliminated helps explain why dosing timing and injection method matter.
After subcutaneous injection, somatropin is absorbed slowly from the injection site into the bloodstream. The absolute bioavailability of subcutaneous somatropin ranges between 70% and 90% depending on the product formulation and injection site. Peak serum concentrations (Cmax) are typically reached approximately 4 to 6 hours after injection. This slow absorption from the subcutaneous tissue is what determines the overall pharmacokinetic profile.
The terminal half-life of somatropin after subcutaneous injection is approximately 2 to 4 hours. This is significantly longer than the intravenous half-life of just 0.4 to 0.6 hours (roughly 20 to 30 minutes). The difference exists because subcutaneous absorption is slow and rate-limiting, meaning the somatropin enters the bloodstream gradually rather than all at once. The volume of distribution at steady state is approximately 50 mL per kilogram of body weight, which approximates the serum volume.
Somatropin is metabolised through classical protein catabolism in both the liver and kidneys. In the kidneys, the protein is filtered and broken down into its constituent amino acids, which return to the systemic circulation. The pharmacokinetics of somatropin are similar in men and women, and similar in adults and children.
IU vs Milligrams: Understanding Somatropin Dosing Units
Somatropin is measured in two units: international units (IU) and milligrams (mg). The conversion between them is approximately 1 mg equals 3 IU, although the exact ratio can vary slightly between manufacturers depending on the specific activity of their product. Most pharmaceutical labels list both values. For example, a 5 mg vial of somatropin contains approximately 15 IU, and an 8.8 mg vial contains approximately 26.4 IU.
In the generic and independently branded market, products are more commonly labelled in IU. A GenXtropin HGH 100IU kit contains 10 vials of 10IU each, which equates to approximately 3.33 mg of somatropin per vial. Understanding this conversion is important when comparing products from different manufacturers or when following dosing protocols that are written in milligrams rather than international units.
Natural Growth Hormone Production and Why It Declines
Your pituitary gland releases growth hormone in pulses throughout the day, not as a constant stream. The largest pulse occurs during the first phase of deep sleep (slow wave sleep), with smaller pulses triggered by exercise, fasting, and other physiological signals. This pulsatile release pattern is regulated by two hypothalamic hormones: growth hormone releasing hormone (GHRH), which stimulates release, and somatostatin, which inhibits it.
Growth hormone production peaks during puberty and begins to decline steadily from the mid-twenties onward. This age related decline is sometimes referred to as somatopause. By the age of 60, most adults produce significantly less growth hormone than they did at 25. The consequences of this decline include increased body fat (particularly visceral fat), decreased lean muscle mass, reduced bone density, thinner skin, slower recovery from injury, and changes in energy and mood. These are the same symptoms seen in adults diagnosed with growth hormone deficiency, which is why exogenous somatropin has applications in both medical treatment and performance enhancement.
When somatropin is injected subcutaneously, it does not replicate the natural pulsatile release pattern. Instead, it creates a single sustained elevation in serum GH levels that peaks after several hours and gradually tapers off. This difference in delivery profile is one reason why timing of injection matters and why experienced users develop specific protocols around when they inject relative to meals, sleep, and training.
How to Assess Somatropin Quality: Lab Testing Explained
Independent laboratory testing is the only objective way to verify what a somatropin product actually contains. The most commonly used testing method is high performance liquid chromatography (HPLC), which separates the components of a sample and measures each one individually. Here is what each part of a lab report tells you.
The most respected independent laboratory in the performance enhancement community is Janoshik Analytical, which accepts submissions from individuals and tests samples for purity, dimer content, and identity. Tests that are submitted independently by customers rather than commissioned by the manufacturer carry more weight because there is no financial incentive to manipulate the results. You can learn more about GenXtropin’s independent lab results and product verification system on the official website.
Somatropin FAQ
Is somatropin the same as HGH?
+
Yes. Somatropin is the international non-proprietary name for synthetic human growth hormone. When produced through recombinant DNA technology with the correct 191 amino acid sequence, somatropin is structurally identical to the growth hormone your pituitary gland produces naturally. The terms HGH, rhGH, GH, somatotropin, and somatropin all describe the same molecule. The distinction is that somatotropin typically refers to the naturally occurring form while somatropin refers to the recombinant (manufactured) version.
What does rDNA origin mean on a somatropin label?
+
The label “rDNA origin” stands for recombinant DNA origin. It means the somatropin was produced using genetically modified bacteria (usually E. coli) that have been programmed with the human growth hormone gene. The bacteria produce the growth hormone protein during fermentation, and it is then extracted, refolded into its bioactive form, purified, and freeze-dried. This method replaced cadaver-derived growth hormone in 1985 and eliminated the risk of prion disease transmission. Every legitimate somatropin product manufactured today uses this technology.
What is the half-life of somatropin?
+
The terminal half-life of somatropin after subcutaneous injection is approximately 2 to 4 hours. After intravenous administration, the half-life is much shorter at around 20 to 30 minutes. The longer half-life seen with subcutaneous injection occurs because the somatropin is absorbed slowly from the injection site, which is the rate-limiting step. Peak serum concentrations are typically reached 4 to 6 hours after subcutaneous injection, and the absolute bioavailability ranges between 70% and 90%.
How can I tell if a somatropin product is genuine?
+
The most reliable method is independent laboratory testing through a service like Janoshik Analytical, where results are submitted publicly and cannot be influenced by the manufacturer. Beyond that, look for brands that offer product verification systems with unique one-time codes. GenXtropin UK includes a scratch-off security sticker on every kit that can be verified online. You should also check community forums for real user reports, look for consistent batch quality, and be aware of known counterfeit products that imitate legitimate brands.
Looking for a Somatropin Product?
GenXtropin HGH 100IU is a somatropin (rDNA origin) product with a 191 amino acid sequence, independently tested by Janoshik Analytical with 90.7% purity and 0.03% dimer. Visit GenXtropin UK to see the full product range, customer reviews, lab test details, and the product verification system.
View GenXtropin HGH